Market Overview

UPDATE: Jefferies Raises PT on Pfizer on Attractive Valuation

Related PFE
Pfizer Inc. Rockets Higher Following Morgan Stanley Upgrade
Benzinga's Top Upgrades
Dow 30 Stock Roundup: NIKE Beats Estimates, Pfizer Ups 2015 Outlook, Microsoft Changes Reporting Structure (Zacks)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), and raised the price target from $31.00 to $33.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Pfizer closed on Tuesday at $29.11.

Latest Ratings for PFE

Oct 2015Morgan StanleyUpgradesEqual-weightOverweight
Aug 2015JefferiesMaintainsBuy
Jun 2015JefferiesInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (PFE)

Get Benzinga's Newsletters